Patents by Inventor Harry John Wadsworth
Harry John Wadsworth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20120020884Abstract: An indole-based in vivo imaging agent is provided by the present invention that binds with high affinity to PBR, has good uptake into the brain following administration, and which has good selective binding to PBR. The invention also includes a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. Also provided is a cassette for automated synthesis of the in vivo imaging agent. Further aspects of the invention include a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, and methods for the use of said in vivo imaging agent.Type: ApplicationFiled: March 26, 2010Publication date: January 26, 2012Inventors: Harry John Wadsworth, Bo Shan, Dennis O'shea, Joanna Marie Passmore, William John Trigg, Amanda Ewan
-
Publication number: 20120020882Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: ApplicationFiled: August 8, 2011Publication date: January 26, 2012Applicant: GE HEALTHCARE ASInventors: Alan Cuthbertson, Bard Indrevoll, Magne Solbakken, Torgrim Engell, Colin Mill Archer, Harry John Wadsworth
-
Publication number: 20120003154Abstract: The present invention provides a novel radiolabeled aryloxyalinine derivative suitable for in vivo imaging. In comparison to known aryloxyalinine derivative in vivo imaging agents, the in vivo imaging agent of the present invention has better properties for in vivo imaging. The in vivo imaging agent of the present invention demonstrates good selective binding to the peripheral benzodiazepine receptor (PBR), in combination with good brain uptake and in vivo kinetics following administration to a subject.Type: ApplicationFiled: March 19, 2010Publication date: January 5, 2012Inventors: Harry John Wadsworth, William John Trigg
-
Patent number: 8066974Abstract: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds. More specifically the iodine containing compounds are chemical compounds containing an aliphatic central moiety containing urea or urethane functions allowing for the arrangement of three iodinated phenyl groups bound thereto. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging and to contrast media containing such compounds.Type: GrantFiled: May 10, 2007Date of Patent: November 29, 2011Assignee: GE Healthcare ASInventors: Duncan Wynn, Harry John Wadsworth, Ian Martin Newington
-
Publication number: 20110200536Abstract: The present invention relates to chelators, in particular to chelators which are capable of forming complexes, i.e. paramagnetic chelates, with paramagnetic metal ions. The invention also relates to said paramagnetic chelates, said paramagnetic chelates linked to other molecules and their use as contrast agents in magnetic resonance imaging (MRI).Type: ApplicationFiled: August 12, 2008Publication date: August 18, 2011Inventors: Harry John Wadsworth, Ian Martin Newington, Dennis O'shea
-
Publication number: 20110196149Abstract: A method for the fluoridation of an iodonium salt with a fluoride ion source which can be carried out in an aqueous reaction solvent.Type: ApplicationFiled: April 18, 2011Publication date: August 11, 2011Applicant: GE HEALTHCARE LIMITEDInventors: HARRY JOHN WADSWORTH, PETER ANTHONY DEVENISH
-
Patent number: 7994134Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: GrantFiled: April 15, 2009Date of Patent: August 9, 2011Assignee: GE Healthcare ASInventors: Alan Cuthbertson, Bård Indrevoll, Magne Solbakken, Torgrim Engell, Colin Mill Archer, Harry John Wadsworth
-
Publication number: 20110190618Abstract: The present invention concerns in vivo imaging and in particular in vivo imaging of the peripheral benzodiazepine receptor (PBR). A tetracyclic indole in vivo imaging agent is provided that binds with high affinity to PBR, has good uptake into the brain following administration, and which preferentially binds to tissues expressing higher levels of PBR. The present invention also provides a precursor compound useful in the synthesis of the in vivo imaging agent of the invention, as well as a method for synthesis of said in vivo imaging agent comprising use of said precursor compound, and a kit for carrying out said method. A cassette for the automated synthesis of the in vivo imaging agent is also provided. In addition, the invention provides a radiopharmaceutical composition comprising the in vivo imaging agent of the invention, as well as methods for the use of said in vivo imaging agent.Type: ApplicationFiled: October 2, 2009Publication date: August 4, 2011Inventors: Harry John Wadsworth, Bo Shan, Dennis O' Shea, Joanna Marie Passmore, William John Trigg
-
Patent number: 7976824Abstract: The invention relates to a compound of formula (I): wherein P1, P2, P3, and P4 are each independently hydrogen or a protecting group; and n is an integer of from 2 to 20 and to the use of such compounds for the synthesis of 18F-FDG.Type: GrantFiled: July 29, 2004Date of Patent: July 12, 2011Assignee: GE Healthcare LimitedInventors: Lynda Jane Brown, Richard Charles Downie Brown, Harry John Wadsworth, Alexander Jackson
-
Patent number: 7935852Abstract: A method for the fluoridation of an iodonium salt with a fluoride ion source which can be carried out in an aqueous reaction solvent.Type: GrantFiled: April 6, 2005Date of Patent: May 3, 2011Assignee: GE Healthcare LimitedInventors: Harry John Wadsworth, Peter Anthony Devenish
-
Patent number: 7919071Abstract: The present invention relates to a contrast agent of Formula I V-L-Z Formula I where V is a non-peptidic vector having affinity for the Angiotensin II receptor, L is a bond, a spacer or a linker moiety and Z represents a moiety detectable in an in vivo imaging procedure of a human or animal body.Type: GrantFiled: January 9, 2004Date of Patent: April 5, 2011Assignee: GE Healthcare ASInventors: Magne Solbakken, Torgrim Engell, Harry John Wadsworth, Colin M. Archer
-
Publication number: 20110070161Abstract: The present invention provides a PET tracer that has improved properties for imaging the peripheral benzodiazepine receptor (PBR) as compared with known such PET tracers. The present invention also provides a precursor compound useful in the preparation of the PET tracer of the invention and methods for the preparation of said precursor compound and said PET tracer. Also provided by the present invention is a radiopharmaceutical composition comprising the PET tracer of the invention. Methods for using the PET tracer and the radiopharmaceutical composition are also provided.Type: ApplicationFiled: September 13, 2010Publication date: March 24, 2011Applicant: GE HEALTHCARE LIMITEDInventors: RADHA ACHANATH, SRINATH BALAJI, STEVEN FAIRWAY, AFSAL M. KADAVILPPARAMPU MOHAMED, DIMITRIOS MANTZILAS, UMAMAHESHWAR MOKKAPATI, DENNIS O'SHEA, JOANNA MARIE PASSMORE, BO SHAN, WILLIAM JOHN TRIGG, HARRY JOHN WADSWORTH
-
Publication number: 20100260685Abstract: The present invention relates to a class of compounds and to diagnostic compositions containing such compounds where the compounds are iodine containing compounds of the formula R—Y—X—Z—R where each R denotes a triiodinated phenyl residue further substituted by hydrophilic moieties, Y and Z are urea and urethane groups and X is a alkylene group which may be further substituted. The invention also relates to the use of such diagnostic compositions as contrast agents in diagnostic imaging and in particular in X-ray imaging, and to contrast media containing such compounds.Type: ApplicationFiled: October 29, 2008Publication date: October 14, 2010Inventors: Duncan George Wynn, Ian Martin Newington, Harry John Wadsworth
-
Patent number: 7767796Abstract: The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalized at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimize lipophilicity and steric hulk. Protected versions of the chelators are provided which permit conjugation with a wide range of targeting molecules without interfering reactions with the amine nitrogens of the tetra-amine chelator. Syntheses of the functionalised chelators are described, together with bifunctional chelate precursors. Radiopharmaceutical compositions comprising the technetium metal complexes of the invention are described, together with non-radioactive kits for the preparation of such radiopharmaceuticals.Type: GrantFiled: July 19, 2005Date of Patent: August 3, 2010Assignee: GE Healthcare LimitedInventors: Anthony Eamonn Storey, Harry John Wadsworth, Nigel Anthony Powell, Philip Duncanson
-
Publication number: 20100056787Abstract: The present invention relates to chelating agents, in particular to chelating agents which are capable of forming complexes with paramagnetic metal ions such as iron (III) and gadolinium (III). The invention also relates to the complexes formed and their use as MRI contrast agents.Type: ApplicationFiled: January 11, 2008Publication date: March 4, 2010Applicant: GE Healthcare ASInventors: Harry John Wadsworth, Ian Martin Newington, Clare L. Jones, Amanda Ewan, Dennis O'Sheo
-
Publication number: 20100040542Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal 99mTc, are useful as radiopharmaceuticals.Type: ApplicationFiled: October 1, 2009Publication date: February 18, 2010Applicant: GE HEALTHCARE LIMITEDInventors: COLIN MILL ARCHER, HARRY JOHN WADSWORTH, TORGRIM ENGELL
-
Publication number: 20100008864Abstract: The present invention relates to novel compounds of formula (I) and (II), compositions comprising compounds of formula (II) and their use as contrast agents in magnetic resonance (MR) imaging (MRI) and MR spectroscopy (MRS).Type: ApplicationFiled: July 8, 2009Publication date: January 14, 2010Inventors: Andreas Meijer, Harry John Wadsworth, Ian Martin Newington, Clare L. Jones, Amanda Ewan, Dennis O'Shea, Oskar Axelsson, Anders Brathe, Andreas Olsson, John Henrik Johansen, Duncan George Wynn
-
Patent number: 7642373Abstract: Decomposition of iodonium salts by a free radical process has been identified as a significant factor in the observed yield variability of fluoridation reactions using said iodonium salts. Accordingly, the inclusion of a free radical trap in the reaction mixture blocks the radical chain decomposition pathway for iodonium salts such that only the reaction leading to fluoridation can occur and the yield of aryl fluoride becomes high and reproducible. The reaction may also be carried out on solid phase. In both the solution and the solid phase the preferred method of the present invention is radiofluoridation.Type: GrantFiled: December 17, 2004Date of Patent: January 5, 2010Assignee: GE Healthcare LimitedInventors: Harry John Wadsworth, David Arthur Widdowson, Emmanuelle Wilson, Michael Andrew Carroll
-
Patent number: 7597875Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal99mTc, are useful as radiopharmaceuticals.Type: GrantFiled: July 10, 2002Date of Patent: October 6, 2009Assignee: GE Healthcare LimitedInventors: Colin Mill Archer, Harry John Wadsworth, Torgrim Engell
-
Publication number: 20090203584Abstract: The invention relates to new peptide-based compounds for use as diagnostic imaging agents or as therapeutic agents wherein the agents comprise targeting vectors which bind to integrin receptors.Type: ApplicationFiled: April 15, 2009Publication date: August 13, 2009Inventors: Alan Cuthbertson, Bard Indrevoll, Magne Solbakken, Torgrim Engell, Colin MIll Archer, Harry John Wadsworth